middle.news

How Will Invion Navigate $8.8M Loss Amid Clinical Breakthroughs?

1:02am on Saturday 30th of August, 2025 AEST Healthcare
Read Story

How Will Invion Navigate $8.8M Loss Amid Clinical Breakthroughs?

1:02am on Saturday 30th of August, 2025 AEST
Key Points
  • Net loss increased 56.5% to $8.8 million for FY25
  • No revenue recorded, down 100% from prior year
  • Progress in Phase I/II trials for non-melanoma skin cancer and prostate cancer
  • Raised approximately $2 million via share placement and $980,000 through loyalty option entitlement
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Invion (ASX:IVX)
OPEN ARTICLE